Brind.

Vivos and Mayo Clinic are partnering for a first-in-human feasibility study for RadioGel®, which received FDA approval for its Investigational Device Exemption.

1 report, 1 independent Updated Jul 6
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.

What happened

Some supportReported by 1 outlet

Vivos and Mayo Clinic are partnering for a first-in-human feasibility study for RadioGel®, which received FDA approval for its Investigational Device Exemption.

Who's involved

What this event is mainly about

Keep exploring

The entities involved

Coverage

Newest first; wire copies grouped